Natchiar G N, Thulasiraj R D, Negrel A D, Bangdiwala S, Rahmathallah R, Prajna N V, Ellwein L B, Kupfer C
Aravind Eye Hospital, Madurai, India.
Am J Ophthalmol. 1998 Jan;125(1):1-13. doi: 10.1016/s0002-9394(99)80229-3.
The Madurai Intraocular Lens Study (MIOLS) was designed to compare safety, efficacy, and quality of life outcomes after either intracapsular cataract extraction with aphakic glasses (ICCE-AG) or extracapsular cataract extraction with posterior chamber intraocular lens (ECCE/ PC-IOL).
The Madurai Intraocular Lens Study was a nonmasked randomized controlled clinical trial conducted at a single hospital. Thirty-four hundred patients with age-related cataracts and having a best-corrected visual acuity less than or equal to 20/120 in the better eye were randomly assigned to either of the two cataract operative procedures. The main clinical outcomes were safety (complication rates) and efficacy (best-corrected visual acuity at 1 year equal to or better than 20/40). In addition, a subset of 1,700 trial participants received questionnaires before surgery, at 6 months after surgery, and at 1 year after surgery to measure visual functioning and vision-related quality of life.
Details of study design, study organization, clinical and quality of life outcome variables, sample size calculations, patient eligibility criteria and recruitment, randomization and masking, participant flow, adherence to follow-up, quality assurance, and statistical methods are presented.
The Madurai Intraocular Lens Study has sufficient power to detect clinically significant differences between the treatment options. There were no statistically significant differences between the two treatment groups for any of the major study variables at baseline. A high level of quality assurance was maintained throughout the October 1993 to June 1996 study period. The results should be applicable to all settings where the requisite expertise and resources are present.
马杜赖人工晶状体研究(MIOLS)旨在比较囊内白内障摘除联合无晶状体眼镜(ICCE - AG)或囊外白内障摘除联合后房型人工晶状体(ECCE/PC - IOL)后的安全性、有效性及生活质量结果。
马杜赖人工晶状体研究是在一家医院进行的非盲随机对照临床试验。3400例年龄相关性白内障且较好眼最佳矫正视力小于或等于20/120的患者被随机分配至两种白内障手术方法中的一种。主要临床结果为安全性(并发症发生率)和有效性(1年后最佳矫正视力等于或优于20/40)。此外,1700名试验参与者的一个子集在手术前、手术后6个月和手术后1年接受问卷调查,以测量视觉功能和与视力相关的生活质量。
介绍了研究设计、研究组织、临床和生活质量结果变量、样本量计算、患者入选标准和招募、随机化和设盲、参与者流程、随访依从性、质量保证和统计方法的详细信息。
马杜赖人工晶状体研究有足够的能力检测治疗方案之间临床上的显著差异。在基线时,两个治疗组在任何主要研究变量上均无统计学显著差异。在1993年10月至1996年6月的整个研究期间保持了高水平的质量保证。该结果应适用于所有具备必要专业知识和资源的环境。